NZ538109A - Therapeutic treatment for vegf related occular diseases - Google Patents
Therapeutic treatment for vegf related occular diseasesInfo
- Publication number
- NZ538109A NZ538109A NZ538109A NZ53810997A NZ538109A NZ 538109 A NZ538109 A NZ 538109A NZ 538109 A NZ538109 A NZ 538109A NZ 53810997 A NZ53810997 A NZ 53810997A NZ 538109 A NZ538109 A NZ 538109A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- vegf
- independently
- hydrogen
- retinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1665896P | 1996-05-01 | 1996-05-01 | |
US08/841,739 US6114320A (en) | 1996-05-01 | 1997-04-30 | Therapeutic treatment for VEGF related ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ538109A true NZ538109A (en) | 2006-10-27 |
Family
ID=26688915
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ332833A NZ332833A (en) | 1996-05-01 | 1997-05-01 | Use of bis-indolylmaleimides to treat VEGF related ocular diseases |
NZ538109A NZ538109A (en) | 1996-05-01 | 1997-05-01 | Therapeutic treatment for vegf related occular diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ332833A NZ332833A (en) | 1996-05-01 | 1997-05-01 | Use of bis-indolylmaleimides to treat VEGF related ocular diseases |
Country Status (22)
Country | Link |
---|---|
US (1) | US6114320A (de) |
EP (1) | EP0918519B1 (de) |
JP (1) | JP4122060B2 (de) |
KR (1) | KR100364487B1 (de) |
CN (1) | CN1158073C (de) |
AT (1) | ATE270548T1 (de) |
AU (1) | AU724923B2 (de) |
BR (1) | BR9710705A (de) |
CA (1) | CA2253613C (de) |
CZ (1) | CZ296711B6 (de) |
DE (1) | DE69729798T2 (de) |
EA (1) | EA001752B1 (de) |
ES (1) | ES2224249T3 (de) |
HK (1) | HK1020017A1 (de) |
HU (1) | HU226378B1 (de) |
IL (1) | IL126836A (de) |
NO (1) | NO322209B1 (de) |
NZ (2) | NZ332833A (de) |
PL (1) | PL189020B1 (de) |
PT (1) | PT918519E (de) |
UA (1) | UA54427C2 (de) |
WO (1) | WO1997040831A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723456A (en) * | 1993-12-07 | 1998-03-03 | Eli Lilly & Company | Therapeutic treatment for cardiovascular diseases |
US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
ATE371453T1 (de) * | 1998-08-13 | 2007-09-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von okularen neovaskularen erkrankungen |
US6214819B1 (en) | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
KR100698449B1 (ko) * | 1998-11-23 | 2007-03-23 | 노파르티스 아게 | 안구 혈관신생 질환 치료용 스타우로스포린 유도체의 용도 |
WO2000037502A2 (en) * | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
US6271233B1 (en) | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
US20030119812A1 (en) * | 2001-11-08 | 2003-06-26 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
AU2003254566A1 (en) * | 2002-07-23 | 2004-02-09 | Novartis Ag | Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent |
US20070059381A1 (en) * | 2003-06-20 | 2007-03-15 | Barker Ronnie C | Treatment of amd with combination of ingredients |
JP2007529434A (ja) * | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン, | 視覚サイクルの阻害による網膜症の予防 |
EP2168968B1 (de) | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bizylische ringsubstituierte heterobizyklische Proteinkinasehemmer |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
US7455447B2 (en) * | 2006-05-19 | 2008-11-25 | Mediatek Inc. | Method and apparatus for a portable device |
EP2056831A2 (de) * | 2006-08-23 | 2009-05-13 | Novartis AG | Verwendung von pkc-hemmern in speziellen indolylmaleimid-derivaten bei augenkrankheiten |
CA2665490C (en) * | 2006-10-03 | 2014-06-17 | The Trustees Of The University Of Pennsylvania | Method for treatment of macular degeneration |
WO2016153877A1 (en) * | 2015-03-26 | 2016-09-29 | Eyekor, Llc | Image analysis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
HUT69164A (en) * | 1993-12-07 | 1995-08-28 | Lilly Co Eli | Improved process for producing bis-indolyl-maleimide derivatives |
RU2147304C1 (ru) * | 1993-12-07 | 2000-04-10 | Эли Лилли Энд Компани | Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция |
US5545636A (en) * | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
US5481003A (en) * | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
US5491242A (en) * | 1994-06-22 | 1996-02-13 | Eli Lilly And Company | Protein kinase C inhibitors |
-
1997
- 1997-01-05 UA UA98116304A patent/UA54427C2/uk unknown
- 1997-04-30 US US08/841,739 patent/US6114320A/en not_active Expired - Lifetime
- 1997-05-01 EA EA199800970A patent/EA001752B1/ru not_active IP Right Cessation
- 1997-05-01 CA CA002253613A patent/CA2253613C/en not_active Expired - Fee Related
- 1997-05-01 AU AU29361/97A patent/AU724923B2/en not_active Ceased
- 1997-05-01 EP EP97923594A patent/EP0918519B1/de not_active Expired - Lifetime
- 1997-05-01 HU HU9902805A patent/HU226378B1/hu not_active IP Right Cessation
- 1997-05-01 CN CNB971956995A patent/CN1158073C/zh not_active Expired - Fee Related
- 1997-05-01 JP JP53929897A patent/JP4122060B2/ja not_active Expired - Fee Related
- 1997-05-01 ES ES97923594T patent/ES2224249T3/es not_active Expired - Lifetime
- 1997-05-01 AT AT97923594T patent/ATE270548T1/de active
- 1997-05-01 KR KR10-1998-0708799A patent/KR100364487B1/ko not_active IP Right Cessation
- 1997-05-01 DE DE69729798T patent/DE69729798T2/de not_active Expired - Lifetime
- 1997-05-01 PT PT97923594T patent/PT918519E/pt unknown
- 1997-05-01 BR BR9710705A patent/BR9710705A/pt not_active Application Discontinuation
- 1997-05-01 WO PCT/US1997/007800 patent/WO1997040831A1/en active IP Right Grant
- 1997-05-01 NZ NZ332833A patent/NZ332833A/en unknown
- 1997-05-01 NZ NZ538109A patent/NZ538109A/en not_active IP Right Cessation
- 1997-05-01 CZ CZ0349998A patent/CZ296711B6/cs not_active IP Right Cessation
- 1997-05-01 PL PL97330463A patent/PL189020B1/pl not_active IP Right Cessation
- 1997-05-01 IL IL12683697A patent/IL126836A/en not_active IP Right Cessation
-
1998
- 1998-10-30 NO NO19985067A patent/NO322209B1/no not_active IP Right Cessation
-
1999
- 1999-11-19 HK HK99105357A patent/HK1020017A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0918519B1 (de) | Therapeutische behandlung von vegf-bedingten augenkrankheiten | |
WO1997040831A9 (en) | Therapeutic treatment for vegf related occular diseases | |
AU736333B2 (en) | Therapeutic treatment for VEGF related diseases | |
US10894043B2 (en) | Pharmaceutical composition | |
EP2156833A1 (de) | Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht-ergot-d2-rezeptoragonist als wirkstoff | |
US10130634B2 (en) | Therapeutic agent for ophthalmic disease | |
KR20070040326A (ko) | 백내장, 황반 변성 및 다른 안과 질환의 개선 | |
CN115443132A (zh) | 色满卡林前药的受控递送 | |
JP2012006918A (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤 | |
MXPA98009160A (en) | Therapeutic treatment of ocular diseases related to the vascular endothelial growth factor (ve | |
WO2010056710A1 (en) | Compositions and methods for treating eye diseases | |
JPH04247036A (ja) | 縮瞳をおこすことなく眼圧を下げる治療方法 | |
MXPA98009159A (en) | Therapeutic treatment of diseases related to the vascular endothelial growth factor (ve | |
EP3170500A1 (de) | Prophylaktikum oder therapeutikum für erkrankungen des hinteren augensegments | |
WO2001058487A1 (fr) | Agent therapeutique et/ou prophylactique contre les affections de la retine et du nerf optique | |
KR20000035863A (ko) | Hiv 감염과 관련된 중추 신경계 질환 치료용 약제를 제조하기 위해 pkc의 억제제를 사용하는 방법 | |
MXPA99001960A (en) | Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection | |
MXPA99001961A (en) | Use of pkc inhibitors for the manufacture of a medicament for the treatment of htlv-1 infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S881 | Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office) |
Free format text: THE NAMES OF THE APPLICANTS HAVE BEEN CORRECTED TO READ AS ABOVE |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
EXPY | Patent expired |